Paper Details

  1. Home
  2. Paper Details

A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.

Author: BergendahlGenevieve, BrownValerie I, ByronSara A, DykemaKarl J, EslinDon, FergusonWilliam, HannaGina, HansonDerek, HarrodVirginia L, HendricksWilliam P D, IsakoffMichael S, KimElizabeth, KravekaJacqueline M, LewisElizabeth C, MitchellDeanna, NagulapallyAbhinav B, OesterheldJavier, RawwasJawhar, RobertsWilliam D, Saulnier ShollerGiselle L, SerranoJonathan, SnuderlMatija, TrentJeffrey M, WadaRandal K

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the safety and feasibility of adding targeted agents to induction therapy and adding DFMO to immunotherapy for high-risk neuroblastoma (HRNB). The addition of targeted agents did not lead to toxicities that required dose reduction of chemotherapy or permanent discontinuation of the targeted agent. DFMO was well-tolerated and resulted in no unexpected adverse events.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Survival for patients with high-risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapies. AIMS: To study the feasibility and safety of incorporating a genomic-based targeted agent to induction therapy for HRNB as well as the feasibility and safety of adding difluor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675391/

データ提供：米国国立医学図書館（NLM）

A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma

Neuroblastoma, a type of childhood cancer, can be particularly aggressive, especially in high-risk cases. This study investigates a novel treatment approach for high-risk neuroblastoma, combining personalized genomic-guided therapy with immunotherapy. The researchers explored the feasibility and safety of incorporating a targeted agent based on individual tumor profiles and adding difluoromethylornithine (DFMO) to anti-GD2 immunotherapy. They discovered that [主要な発見] This study offers a promising new avenue for treating high-risk neuroblastoma and could potentially improve outcomes for these young patients.

Personalized Cancer Treatment: A New Frontier

This study provides valuable evidence for [社会的な意義] The findings suggest that personalized genomic-guided therapy, paired with immunotherapy, could be a powerful tool in the fight against high-risk neuroblastoma.

Hope for High-Risk Neuroblastoma: A More Targeted Approach

This study offers a glimmer of hope for children battling high-risk neuroblastoma. The findings suggest that [健康的なベネフィットもしくはリスク] for these patients. While further research is needed to confirm long-term efficacy, this pilot study demonstrates the potential of personalized medicine and immunotherapy in treating this challenging cancer.

Dr.Camel's Conclusion

Imagine neuroblastoma as a shifting sandstorm, constantly threatening to engulf the body. This study presents a new strategy for combating this disease, using a targeted approach to fight the storm. By leveraging genomic information and immunotherapy, this research provides hope for a brighter future for children with high-risk neuroblastoma. It's like finding a hidden oasis in the desert, offering respite and a chance for recovery.

Date :
  1. Date Completed 2022-11-22
  2. Date Revised 2023-01-23
Further Info :

Pubmed ID

35355452

DOI: Digital Object Identifier

PMC9675391

Related Literature

Article Analysis
・Effects of eflornithine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.